Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Shares Issued (2023 - 2025)

Immunome's Shares Issued history spans 3 years, with the latest figure at $432.4 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 11489.39% year-over-year to $432.4 million; the TTM value through Dec 2025 reached $477.3 million, up 14947.29%, while the annual FY2025 figure was $45.9 million, 1130.15% up from the prior year.
  • Shares Issued reached $432.4 million in Q4 2025 per IMNM's latest filing, up from $44.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $432.4 million in Q4 2025 to a low of -$1.0 million in Q3 2024.
  • Average Shares Issued over 3 years is $66.4 million, with a median of $300000.0 recorded in 2024.
  • The largest YoY upside for Shares Issued was 11489.39% in 2025 against a maximum downside of 171.0% in 2025.
  • A 3-year view of Shares Issued shows it stood at $125.0 million in 2023, then tumbled by 97.01% to $3.7 million in 2024, then skyrocketed by 11489.39% to $432.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Shares Issued are $432.4 million (Q4 2025), $44.9 million (Q3 2025), and -$213000.0 (Q2 2025).